Fosun International Announces 2024 Annual Results: Total Revenue Reaches RMB192.14 Billion, Industrial Operation Profit Amounts to RMB4.9 Billion, Overall Operational Fundamentals Remain Stable
2024 Annual Results Highlights: Total revenue reached RMB192.14 billion; Industrial operation profit amounted to RMB4.9 billion; Total revenue generated by the four core subsidiaries amounted to RMB134.65 billion, accounting for 70.1% of the Group's...
Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY
SHANGHAI, March 24, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius' total revenue reached approximately RMB5.7244 billion, representing an increase of 6.1% YoY. The net profit reached...
Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 mAb HLX22 in the U.S. for Gastric Cancer
SHANGHAI, March 19, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, the company's innovative anti-HER2 monoclonal antibody...
Guo Guangchang: Fosun Emphasizes Strategic Advancement and Exits, Focuses on Core Businesses, and Leverages Operational Capabilities to Participate in Global Markets
HONG KONG, Feb. 25, 2025 /PRNewswire/ -- On 21 February, Guo Guangchang, Chairman of Fosun International spoke at the 25th Annual Conference of Yabuli China Entrepreneurs Forum 2025, stating that private enterprises are not afraid of competition as...